Stanford phd candidate Calvin schmidt posts about investing opportunities in synthetic biology. Available for consulting on potential investments in this area.

Calvin Schmidt Synthetic Biology Index: February Update

Performance overview

Value at beginning of month: $121,630.83

Value at end of month: $148,917.34

Month over month change: +22.43%

Total IRR: 20.51%

Related indices, monthly change

NASDAQ: +6.01%

IVV (iShares Core S&P 500): +6.32%

IBB (iShares NASDAQ Biotechnology Index): +7.32%

MXI (iShares Global Materials): +4.68%

VEGI (iShares MSCI Global Agriculture Producers): +1.37%

ICLN (iShares Clean Energy): +5.68%

Individual performances


Another great month for the index, we saw several huge news events leading to large increases in value for certain companies. Spark Therapeutics led the group when it was announced that they will be acquired by Roche. This news also lifted the value of a number of other medical stocks, as gene therapies continue to drive value. Amyris also had a huge jump on news of a major partnership for the production of cannabinoids. Intrexon, on the other hand, fell over 30% after a disappointing quarter.

Changes made to index

Spark Therapeutics was removed due to their acquisition.

You can view the index here.

Allocation as of March 1, 2019


Calvin Schmidt Synthetic Biology Index: March Update

Calvin Schmidt Synthetic Biology Index: January Update